Screener / SEC EDGAR /CIK 0001638833 /10-K filed Mar 2, 2026, compared with Mar 7, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Hospitals

Surgery Partners, Inc. SGRY

Compare with peers Embed
FY2025 at a glance

Sales up 6.2%, free cash flow down to $195.6M

XBRL, from each 10-K
RevenueStatements
$3.3B from $3.1B in FY2024
FY2015FY2025
Net incomeStatements
-$77.9M from -$168.1M in FY2024
FY2015FY2025
Free cash flowStatements
$195.6M from $209.7M in FY2024
FY2015FY2025
EPS (diluted)Statements
$-0.61 from $-1.33 in FY2024
FY2015FY2025
Operating marginStatements
11.8% from 11.2% in FY2024
FY2015FY2025
Total debtStatements
$3.7B from $3.4B in FY2024
FY2015FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (42)
EPS (ttm)
-0.67
Sales (ttm)
3.4B
Net income (ttm)
-87.0M
Sales growth
+6.2%
EPS growth
-
Sales Q/Q
-0.8%
Free cash flow
202.8M
Gross margin
-
Oper. margin
10.8%
Net margin
-2.6%
FCF margin
6.0%
R&D / sales
-
Dividend
-
Debt/Eq
1.84
Curr. ratio
2.17
Cash
354.5M
Op. cash flow (ttm)
277.9M
EBITDA
565.5M
EBITDA margin
17.1%
Net debt
2.7B
Quick ratio
1.97
Interest cover
1.52
ROIC
7.0%
FCF after stock pay
180.8M
Debt / FCF (years)
15.62
Goodwill / assets
64.0%
Oper. margin low 5y
11.2%
Tax rate
15.4%
Stock pay / sales
0.4%
Shares out.
130.9M
Shares Y/Y
+0.9%
Book / share
12.72
Cash / share
2.71
Sales / share
25.67
Asset turnover
0.48
Days sales out.
66
Sales 3Y CAGR
+9.2%
Sales 5Y CAGR
+12.2%
Employees
16,000
Sales / employee
210K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2015 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.3B +14.7% a year Net income -77.9M
FY2015 revenue 959.9M · Revenues, 0001638833-17-000007 FY2015 net income 1.4M · NetIncomeLoss, 0001638833-17-000007 959.9M FY2015 FY2016 revenue 1.1B · Revenues, 0001638833-17-000007 FY2016 net income 9.5M · NetIncomeLoss, 0001638833-17-000007 1.1B FY2016 FY2018 revenue 1.8B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-21-000034 FY2018 net income -205.7M · NetIncomeLoss, 0001638833-21-000034 1.8B FY2018 FY2019 revenue 1.8B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-22-000019 FY2019 net income -74.8M · NetIncomeLoss, 0001638833-22-000019 1.8B FY2019 FY2020 revenue 1.9B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-23-000021 FY2020 net income -116.1M · NetIncomeLoss, 0001638833-23-000021 1.9B FY2020 FY2021 revenue 2.2B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-24-000029 FY2021 net income -70.9M · NetIncomeLoss, 0001638833-24-000029 2.2B FY2021 FY2022 revenue 2.5B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-25-000053 FY2022 net income -54.6M · NetIncomeLoss, 0001638833-25-000053 2.5B FY2022 FY2023 revenue 2.7B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-26-000008 FY2023 net income -11.9M · NetIncomeLoss, 0001638833-26-000008 2.7B FY2023 FY2024 revenue 3.1B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-26-000008 FY2024 net income -168.1M · NetIncomeLoss, 0001638833-26-000008 3.1B FY2024 FY2025 revenue 3.3B · RevenueFromContractWithCustomerIncludingAssessedTax, 0001638833-26-000008 FY2025 net income -77.9M · NetIncomeLoss, 0001638833-26-000008 3.3B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2015 to FY2025 (9 years).

From the same starting line, FY2015 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2015. What happened, from the 10-Ks. Not a forecast.

FY2015 = 100
100 200 300 400 Revenue: $959.9M in FY2015, $3.3B in FY2025 REVENUE $3.3B · 3.4x Free cash flow: $51.0M in FY2015, $195.6M in FY2025 FREE CASH FLOW $195.6M · 3.8x FY2015 = 100FY2021FY2025
Revenue 3.4x $959.9M to $3.3B
Free cash flow 3.8x $51.0M to $195.6M

Growth per share, FY2014 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +6.9% a year FY2018 $8.42 to FY2025 $13.47, 7 years
Free cash flow per share -4.9% a year FY2018 $2.18 to FY2025 $1.54, 7 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$0.61$13.47$1.54
Dec 31, 2024 -$1.33$14.19$1.66
Dec 31, 2023 -$0.09$15.82$1.63
Dec 31, 2022 -$0.59$21.73$0.85
Dec 31, 2021 -$1.12$15.04$0.41
Dec 31, 2020 -$3.19$2.37$4.18
Dec 31, 2019 -$2.29$6.15$1.16
Dec 31, 2018 -$4.96$8.42$2.18
Dec 31, 2016 $0.20$0.20$1.79
Dec 31, 2015 $0.04-$0.11$1.36
Dec 31, 2014 -$2.04-$8.18$0.44

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.2B
  • − All liabilities (total assets less equity) $6.4B
  • = Net current asset value -$5.3B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.7B
  • − Goodwill $5.2B
  • − Other intangible assets $41.0M
  • = Tangible book value -$3.5B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result. This company does not tag total liabilities, so total assets less equity is used (it includes any non-controlling interest).

SGRY against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+6.2%106th of 155 · median +10.5%
Net margin
-4.1%15.3%
-2.6%113th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-5.2%108th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
6.0%93rd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.8495th of 108 · median 0.69
SGRY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
SGRY Surgery Partners, Inc.$3.4B +6.2%--2.6%-5.2%6.0%1.84
VEEV Veeva Systems$3.5B +16.3%75.0%29.3%13.7%--
ACHC Acadia Healthcare Company, Inc.$3.4B +5.0%--33.1%-55.8%-0.7%1.16
WST West Pharmaceutical Services$3.4B +6.3%37.6%18.8%21.5%13.3%0.07
AMRX Amneal Pharmaceuticals, Inc.$3.2B +8.0%40.2%4.2%25.1%2.8%5.53
PODD Insulet Corporation$3.2B +30.7%71.9%13.4%27.1%8.2%0.61
All 162 companies in the group

Where the $3.3B of revenue came from

by product, year to Dec 31, 2025

  • Private insurance $1.7B · 51%
  • Government $1.4B · 42%
  • Self-pay $87.6M · 3%
  • Other service revenues $82.4M · 2%
  • Other $71.2M · 2%

From the segment tables in the 10-K XBRL.

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -4.5% FY2020: -100.4% net income ÷ equity
Net margin -2.4% FY2020: -6.2% profit per $ of sales: -77.9M ÷ 3.3B
Asset turnover 0.41× FY2020: 0.34× sales per $ of assets: 3.3B ÷ 8.1B
Leverage 4.74× FY2020: 46.83× assets per $ of equity: 8.1B ÷ 1.7B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -2.6% vs 6.8%
  • Return on equity below 15%
    -5.2%
  • A profit in 2 of 10 years
Net margin, FY2015 to FY2025: 0.1% to -2.4%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 1.5× interest expense
  • Debt larger than equity
    Debt / equity 1.84 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.17
  • Net debt over 3 years of free cash flow
    $2.7B net debt, 13.3 years
Debt / equity at each year end, FY2015 to FY2025: 152.37 to 2.18

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $195.6M last year
  • Share count up over 5 years
    +73.9%
Free cash flow, FY2015 to FY2025: 51.0M to 195.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$3.7B of principal due, schedule of Dec 31, 2025

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

SGRY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.3B
FY2015: 959.9MFY2016: 1.1BFY2018: 1.8BFY2019: 1.8BFY2020: 1.9BFY2021: 2.2BFY2022: 2.5BFY2023: 2.7BFY2024: 3.1BFY2025: 3.3B FY2016FY2019FY2021FY2023FY2025
Net income-77.9M
FY2015: 1.4MFY2016: 9.5MFY2018: -205.7MFY2019: -74.8MFY2020: -116.1MFY2021: -70.9MFY2022: -54.6MFY2023: -11.9MFY2024: -168.1MFY2025: -77.9M FY2016FY2019FY2021FY2023FY2025
Free cash flow195.6M
FY2015: 51.0MFY2016: 86.1MFY2018: 104.8MFY2019: 55.9MFY2020: 204.0MFY2021: 29.5MFY2022: 78.2MFY2023: 205.0MFY2024: 209.7MFY2025: 195.6M FY2016FY2019FY2021FY2023FY2025
Free cash flow after stock pay180.8M
FY2015: 43.5MFY2016: 84.1MFY2018: 95.5MFY2019: 45.7MFY2020: 190.8MFY2021: 12.1MFY2022: 59.8MFY2023: 187.3MFY2024: 176.4MFY2025: 180.8M FY2016FY2019FY2021FY2023FY2025
EPS (diluted)-0.61
FY2015: 0.04FY2016: 0.20FY2018: -4.96FY2019: -2.29FY2020: -3.19FY2021: -1.12FY2022: -0.59FY2023: -0.09FY2024: -1.33FY2025: -0.61 FY2016FY2019FY2021FY2023FY2025
Diluted shares127.2M
FY2015: 37.5MFY2016: 48.2MFY2018: 48.0MFY2019: 48.3MFY2020: 48.8MFY2021: 72.4MFY2022: 92.0MFY2023: 125.6MFY2024: 126.1MFY2025: 127.2M FY2016FY2019FY2021FY2023FY2025

The segments changed

10-K filed Mar 2, 2026
We were not engaged to audit, review, or apply any procedures to the disclosure of significant expenses and other segment items or the recast of the segment disclosures to reflect one reportable segment in Note 14 to the financial statements, and accordingly, we do not express an opinion or any other form of assurance about whether such retrospective adjustments are appropriate and have been properly applied. 10-K

When a company changes its segments, the years before are usually recast, so growth by segment is not comparable with what earlier 10-Ks showed. Found by comparing the segments with revenue in the last two 10-Ks (XBRL) and by the 10-K's own words, without AI.

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Patient service revenues 3.2B97.5% +5.6%
Private insurance 1.7B51.0% +3.2%
Government 1.4B41.7% +9.8%
Self-pay 87.6M2.6% +6.4%
Other service revenues 82.4M2.5% +37.6%
Other 71.2M2.2% -12.2%

10-K 0001638833-26-000008, segment and revenue notes (XBRL).

Revenue by business segment, 5 years

from the segment notes of the last 3 10-Ks
FY2021FY2022FY2023FY2024FY2025
Surgical Facilities-2.5B2.7B3.1B3.3B
Ancillary Services67.3M68.9M67.5M--
Surgical Facility Services2.2B2.5B2.7B--

Revenue and operating income by business segment, as each 10-K reports them in its segment note (XBRL). Each year comes from the newest 10-K that reports it, so a year the company later recast shows the recast number; click a number to open that 10-K. Segments changed: FY2021, FY2022, FY2023 are in italics, as first reported under the earlier segments, so they are not comparable with the later years. Rows without a number were not reported as a separate segment that year. "Corporate and other" and "All other" are the 10-K's own lines for what is outside the segments.

Income statement

From EDGAR
FY2015FY2016FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue959.9M1.1B1.8B1.8B1.9B2.2B2.5B2.7B3.1B3.3B
Cost of revenue669.3M821.2M1.4B1.4B------
SG&A56.0M60.2M93.6M88.6M97.1M104.0M102.2M120.9M138.7M118.2M
Operating income144.8M196.5M77.8M235.9M183.0M302.2M345.2M328.0M348.8M389.5M
Interest expense96.8M79.3M145.4M180.3M203.6M194.3M218.7M169.6M199.7M256.8M
Pretax income-76.1M92.2M-69.2M54.6M-18.8M81.2M110.3M135.0M147.1M116.9M
Income tax-149.0M7.1M26.4M9.5M-20.1M10.5M23.3M-300K134.6M18.0M
Net income1.4M9.5M-205.7M-74.8M-116.1M-70.9M-54.6M-11.9M-168.1M-77.9M
EPS (diluted)0.040.20-4.96-2.29-3.19-1.12-0.59-0.09-1.33-0.61
Diluted shares37.5M48.2M48.0M48.3M48.8M72.4M92.0M125.6M126.1M127.2M
Depreciation & amortization34.5M39.6M67.4M76.5M94.8M98.8M114.8M118.1M152.6M176.0M
EBITDA179.3M236.0M145.2M312.4M277.8M401.0M460.0M446.1M501.4M565.5M
Operating margin15.1%17.2%4.4%12.9%9.8%13.6%13.6%12.0%11.2%11.8%
Net margin0.1%0.8%-11.6%-4.1%-6.2%-3.2%-2.2%-0.4%-5.4%-2.4%
Revenue growth+138%+19.3%-+3.4%+1.6%+19.6%+14.1%+8.0%+13.5%+6.2%
EPS growth-+400%--------

Stock-based pay and leases

From EDGAR
FY2015FY2016FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)7.5M2.0M9.3M10.2M13.2M17.4M18.4M17.7M33.3M14.8M
Stock-based pay / revenue0.8%0.2%0.5%0.6%0.7%0.8%0.7%0.6%1.1%0.4%
Operating lease cost---70.4M74.1M76.4M65.5M65.7M65.8M64.4M
Operating lease cash paid---67.3M68.1M74.3M63.2M63.7M62.8M61.3M
Finance lease principal paid---13.4M18.3M20.1M24.6M26.7M33.0M39.2M
Right-of-use assets--0297.7M310.1M324.1M279.1M255.3M295.7M289.2M
Operating lease liabilities--0320.4M340.1M355.7M307.9M286.5M333.1M322.6M
Finance lease liabilities--25.4M253.4M281.2M364.6M585.7M693.6M798.7M935.5M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SGRY/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.